Dramatic rise in the proportion of ESBL-producing Escherichia coli and Klebsiella pneumoniae among clinical isolates identified in Canadian hospital laboratories from 2007 to 2016
| Autor: | James A. Karlowsky, Daryl J. Hoban, Heather J. Adam, Michael R. Mulvey, Andrew J Denisuik, George G. Zhanel, Canward, Philippe Lagacé-Wiens, Melanie R. Baxter |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male Microbiology (medical) Canada Adolescent Genotype Klebsiella pneumoniae Microbial Sensitivity Tests Tigecycline Meropenem beta-Lactamases Microbiology Young Adult chemistry.chemical_compound Bacterial Proteins Drug Resistance Bacterial Escherichia coli polycyclic compounds medicine Humans Pharmacology (medical) Escherichia coli Infections Aged Pharmacology Antiinfective agent biology Broth microdilution Middle Aged biochemical phenomena metabolism and nutrition Laboratories Hospital bacterial infections and mycoses biology.organism_classification Anti-Bacterial Agents Klebsiella Infections Infectious Diseases chemistry Amikacin Colistin bacteria Female Ertapenem medicine.drug |
| Zdroj: | Journal of Antimicrobial Chemotherapy. 74:iv64-iv71 |
| ISSN: | 1460-2091 0305-7453 |
| Popis: | Objectives To assess the prevalence, antimicrobial susceptibilities and molecular characteristics of ESBL-producing Escherichia coli and Klebsiella pneumoniae infecting patients receiving care in Canadian hospitals from January 2007 to December 2016. Methods Clinical isolates of E. coli (n = 8387) and K. pneumoniae (n = 2623) submitted to CANWARD, an ongoing Canadian national surveillance study, were tested using the CLSI reference broth microdilution method to determine their susceptibility to 15 antimicrobial agents. ESBL-producing E. coli and K. pneumoniae confirmed by the CLSI phenotypic method and putative AmpC-producing E. coli underwent PCR testing and DNA sequencing to identify resistance genes. Annual proportions of isolates harbouring ESBL and AmpC genes were assessed by the Cochran–Armitage test of trend. Results The annual proportion of isolates of E. coli that were ESBL producing increased from 3.4% in 2007 to 11.1% in 2016 (P 95% of ESBL-producing E. coli were susceptible to amikacin, colistin, ertapenem, meropenem and tigecycline. The proportion of isolates of K. pneumoniae that were ESBL producing increased from 1.3% in 2007 to 9.7% in 2016 (P 95% of ESBL-producing K. pneumoniae were susceptible to amikacin and meropenem. CTX-M-15 was the predominant genotype in both ESBL-producing E. coli (64.2% of isolates) and ESBL-producing K. pneumoniae (51.0%). The annual proportion of isolates of E. coli that were AmpC producing [annual proportion mean 1.9% (range 0.3%–3.1%)] was unchanged from 2007 to 2016 (P > 0.5). Conclusions The prevalence of both ESBL-producing E. coli and K. pneumoniae increased significantly in Canada during the study period while the prevalence of AmpC-producing E. coli remained low and stable. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|